| Website | novimmune.com |
| Category | BioTech |
| Phone | +41 22 839 71 41 |
| Employees | |
| Founded | 1998 |
| Description | Therapeutic monoclonal antibodies |
| Total | $155M |
| Series A, 5/00 Novartis Venture Fund LODH Immunology Fund | $14M |
| Series B, 2/05 | $13M |
| Series C, 6/06 BZ Bank | $53M |
| Series D, 5/09 BZ Bank Novartis Venture Fund LODH Immunology Fund Varuma AG Pictet Private Equity Investors S.A. Ingro Finanz AG Aravis Ventures | $54.8M |
| Series B, 12/10 BZ Bank | $20.6M |
NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.
